Accessibility StatementSkip Navigation PITTSBURGH, Nov. 6, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today reported strong third quarter 2025 financial results and updated full-year financial guidance. Executive Commentary Continue Reading View PDF Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance View PDF Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance "We delivered another strong quarter by staying focused on our 2025 strategic prioritie ...

Core Insights - Viatris Inc. has received FDA approval for Iron Sucrose Injection, a generic intravenous iron replacement product for treating iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD) [1][2] - The approval includes competitive generic therapy designation for specific strengths, allowing for expedited market entry and 180 days of exclusivity [3][21] - The launch of this first-to-market generic is expected to enhance treatment options for CKD patients and strengthen Viatris' generics portfolio [3][4] Company Developments - The FDA approval marks a significant milestone for Viatris, showcasing its technical and manufacturing capabilities in developing complex generic medicines [2][21] - Viatris' pipeline includes other complex injectables, such as ferric carboxymaltose injection, indicating a robust focus on difficult-to-manufacture products [2] - The company aims to increase sustainable access to critical therapies for patients with CKD and IDA through this new product [3] Market Context - Venofer®, the branded version of iron sucrose, had annual sales of approximately $515 million in the U.S. as of June 30, 2025, highlighting the market potential for the generic version [4] - The competitive generic therapy designation is granted for medications with inadequate generic competition, which may expedite the entry of Viatris' product into the market [3]